A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG 337 in Subjects with MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors

Diseases and Conditions Researched

Esophagus; Stomach

What is the purpose of this trial?

This is a multi-centre Phase 2 study. The study will evaluate the activity and safety of ;AMG 337 ;in patients who have ;MET amplified gastric, ;gastroesophageal ;junction or esophageal adenocarcinoma or other ;MET amplified ;solid tumors. The study is designed to estimate the objective response rate of ;AMG 337 ;by tumor type.

Participation Guidelines

Age: 18 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Amgen, Inc.
Last Updated:
Study HIC#: 1402013465